



Pharmacological Approaches of Chronic Obstructive Pulmonary Disease (COPD) and Lung Cancer

Guest Editors:

Dr. Karolina H. Czarnecka-Chrebelska

Department of Biomedicine and Genetics, Medical University of Lodz, Lodz, Poland

Dr. Jinxiang Xi

Department of Biomedical Engineering, Francis College of Engineering, University of Massachusetts, Lowell, MA 01854, USA

Deadline for manuscript submissions:

25 August 2025

Message from the Guest Editors

Chronic obstructive pulmonary disease (COPD) is the third leading cause of death globally. It is characterized by limited lung airflow and tissue damage, often from chronic bronchitis involving airway inflammation and scarring. The progression of inflammation and oxidant–antioxidant imbalances triggers emphysema formation. The presence of COPD is a significant risk factor for lung cancer (LC) development independent of smoking behavior. Current treatments for COPD include inhaled corticosteroids and bronchodilator therapy, but they do not effectively stop disease progression. Due to the intricate nature of its pathophysiology and the potential to worsen symptoms with current therapies, there is a necessity for more precise and effective treatment options. Therefore, understanding the molecular mechanisms behind chronic obstructive pulmonary disease and lung cancer development may improve the current pharmacotherapy as well as indicate new therapeutic targets and procedures. The goal of this Special Issue is to highlight the new scientific achievements related to COPD and LC etiopathogenesis in relation to the therapeutic approaches.





an Open Access Journal by MDPI

Editor-in-Chief

Prof. Dr. Amélia Pilar Rauter

Departamento de Química e
Bioquímica (DQB) e Centro de
Química Estrutural (CQE),
Institute of Molecular Sciences,
Faculdade de Ciências,
Universidade de Lisboa, Lisboa,
Portugal

Message from the Editor-in-Chief

Because of your expertise in the field of drug sciences, I kindly invite you to consider publishing your current work, in the form of a research article or a review, in the open access electronic journal *Pharmaceuticals*.

Pharmaceuticals is characterized by an active editorial board and a dynamic editorial staff. Manuscripts are peer-reviewed and a final decision is provided to authors within 4–6 weeks after submission. Papers are published on the web immediately after acceptance. For details on the submission process or any other matter, please do not hesitate to contact us.

We hope to handle your contribution to *Pharmaceuticals* soon.

Author Benefits

Open Access: free for readers, with [article processing charges \(APC\)](#) paid by authors or their institutions.

High Visibility: indexed within [Scopus](#), [SCIE \(Web of Science\)](#), [PubMed](#), [PMC](#), [Embase](#), [CAPus / SciFinder](#), and [other databases](#).

Journal Rank: JCR - Q1 (Pharmacology and Pharmacy) / CiteScore - Q1 (Pharmaceutical Science)

Contact Us

Pharmaceuticals Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland

Tel: +41 61 683 77 34
www.mdpi.com

mdpi.com/journal/pharmaceuticals
pharmaceuticals@mdpi.com
[X@Pharmaceut_MDPI](https://twitter.com/Pharmaceut_MDPI)